PFIZER INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Determine Long-Term Safety and Tolerability of Pregabalin in Patients With Anxiety Disorders.
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2006-07-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 511
- Registration Number
- NCT00150449
- Locations
Pfizer Investigational Site
Linezolid for the Treatment of Infections Caused by Methicillin Resistant Staphylococcus Aureus in Japan
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2011-05-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 24
- Registration Number
- NCT00150332
- Locations
- 🇯🇵
Pfizer Investigational Site, Okayama, Japan
Evaluation of Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures.
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2015-03-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 337
- Registration Number
- NCT00150293
- Locations
Pfizer Investigational Site
Immediate vs. Deferred Empirical Antifungal Treatment With Voriconazole In Neutropenic Patients
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2012-01-19
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 147
- Registration Number
- NCT00150345
- Locations
- 🇩🇪
Pfizer Investigational Site, Wuerzburg, Germany
A 5-Year Postmarketing Safety Study Of Xalcom In Patients With Open Angle Glaucoma Or Ocular Hypertension
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2008-11-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 976
- Registration Number
- NCT00150267
- Locations
- 🇬🇧
Pfizer Investigational Site, London, United Kingdom
Demonstrate Exubera Works As Well As Avandia When Added To Sulfonylurea + Metformin In Controlling Glucose
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2008-10-31
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 626
- Registration Number
- NCT00150410
- Locations
- 🇲🇽
Pfizer Investigational Site, Mexico Df, Mexico
An Open-Label Study To Assess The Pharmacokinetics, Safety And Toleration Of Vfend®; Following Multiple Dosing With Vfend
Phase 1
Terminated
- Conditions
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2008-09-29
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1
- Registration Number
- NCT00150319
- Locations
- 🇺🇸
Pfizer Investigational Site, Austin, Texas, United States
Combination Study Of CP-751,871 With Paclitaxel And Carboplatin In Advanced Lung Cancer
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-09-07
- Last Posted Date
- 2013-10-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 282
- Registration Number
- NCT00147537
- Locations
- 🇪🇸
Pfizer Investigational Site, Sevilla, Spain
Non-Comparative Study To Evaluate Changes In FMD After Quinapril Therapy In Hypertensive Women
Phase 4
Completed
- Conditions
- First Posted Date
- 2005-09-07
- Last Posted Date
- 2007-04-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 70
- Registration Number
- NCT00147524
- Locations
- 🇭🇺
Pfizer Investigational Site, Szombathely, Hungary
Study To Examine Effect Of CP-866,087 On Consumption And Craving Of Alcohol In Alcohol Dependent Subjects.
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-09-07
- Last Posted Date
- 2012-10-02
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 88
- Registration Number
- NCT00147576
- Locations
- 🇺🇸
Pfizer Investigational Site, San Antonio, Texas, United States
© Copyright 2024. All Rights Reserved by MedPath